Identification of a coumarin based antihistamine as an anti filoviral entry inhibitor
Abstract
Filoviruses, consisting of Ebola virus, Marburg virus and Cuevavirus, cause severe hemorrhagic fevers in humans with high mortality rates up to 90 . Currently, there is no approved vaccine or therapy available for the prevention and treatment of filovirus infection in humans. The recent 2013-2015 West African Ebola epidemic underscores the urgency to develop antiviral therapeutics against these infectious diseases. Our previous study showed that GPCR antagonists, particularly histamine receptor antagonists (antihistamines) inhibit Ebola and Marburg virus entry. In this study, we screened a library of 1,220 antihistamines, identified multiple compounds with potent inhibitory activity against entry of both Ebola and Marburg viruses in human cancer cell lines, and confirmed their anti-Ebola activity in human primary cells. These antihistamines target a late-stage of Ebola virus entry.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 20, 2017
- Accession Number
- AD1037365
Entities
People
- Veronica Soloveva
Organizations
- United States Army Medical Research Institute of Infectious Diseases